Refers to the proportion of brain OGA enzyme bound by FNP-223, measured via PET imaging.

Tau protein is a protein in the cytoskeleton of neurons that is key to stabilizing microtubules, which act as axonal transport pathways and form part of the neuronal structure. In tauopathies, tau protein loses its normal function, and forms NFTs, which disrupt cellular transport and lead to neurodegeneration and neuronal death. Loss of normal tau function and abnormal aggregation are central to PSP pathophysiology; and the modulation of tau O-GlcNAcylation is a therapeutic strategy under investigation.

A group of neurodegenerative disorders characterized by tau deposits in the brain, with symptoms of dementia and parkinsonism.

The remote monitoring and recording of physiological parameters, such as heart rate or ECG, to assess a patient’s long-term functions in real time.

The elapsed time after drug administration at which the highest concentration of the drug in plasma (Cmax) is observed.

The degree to which adverse effects of a treatment can be tolerated by patients without experiencing significant adverse events.

A radioactive compound used in PET imaging to bind selectively a protein. For example, the [18F]-IMA601 binds to the O-GlcNAcase (OGA) enzyme, allowing visualization and measurement of OGA distribution and target engagement in the brain.

An adverse event that appears or worsens during a clinical trial. It helps identify events that are temporally associated with the drug.

A distinct type of astrocytic pathology characterized by the presence of dense, argyrophilic (silver stain-positive) phosphorylated tau-immunopositive inclusions within the proximal processes of astrocytes. Tufted astrocytes are a histopathological hallmark of PSP.